SCHEMBL4474569

SCHEMBL4474569

Cc1ccc(Cl)cc1-c1ccc(CN2CCNC(c3ccccc3)C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.45
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
DRD4 P21917 5/20 0.39
DRD2 P14416 3/20 0.39
DRD3 P35462 3/20 0.39
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
BACE1 P56817 1/20 0.38
LTA4H P09960 1/20 0.38
SIGMAR1 Q99720 1/20 0.37
CYP2D6 P10635 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4481520 0.90 CNR2 (0.53) CNR2BCHEACHEBACE1LTA4H
SCHEMBL4467570 0.84 LTA4H (0.47) CNR2KMT2ADRD4DRD2DRD3
SCHEMBL13708823 0.84 LTA4H (0.47) CNR2KMT2ADRD4DRD2DRD3
SCHEMBL4476530 0.83 CNR2 (0.65) CNR2DRD4BCHEACHEBACE1
SCHEMBL4467039 0.82 CNR2 (0.61) CNR2KMT2AMEN1LTA4HSIGMAR1
SCHEMBL4468477 0.81 CNR2 (0.60) CNR2KMT2AMEN1DRD4DRD2
SCHEMBL3274123 0.79 SIGMAR1 (0.53) KMT2AMEN1DRD4DRD2DRD3
SCHEMBL3274127 0.79 SIGMAR1 (0.53) KMT2AMEN1DRD4DRD2DRD3
SCHEMBL3276041 0.79 SIGMAR1 (0.53) KMT2AMEN1DRD4DRD2DRD3
SCHEMBL4476534 0.79 CNR2 (0.71) CNR2DRD4CYP2D6CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-7595397-B2 Compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-29 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-16 US disclosed
WO-2007070760-A2 COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191340-A1 Compounds Which Modulate The CB2 Receptor CNR1, CNR2, ARRB1 CNR2 2/4885KMT2A 1738/4885MEN1 4355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.